Franck Perraudin: Lp(a) Lowering Alone May Not Be Enough
Franck Perraudin, VP – Cardiovascular TA Head International Commercial and Launch Strategy at Novartis, shared a post on LinkedIn:
“The Phase 3 HORIZON Trial showed that reductions in Lipoprotein(a) (Lp(a)) did not meet its primary endpoint of reducing a composite of cardiovascular death.
This is for sure a set back, a deception for ASCVD patients with elevated Lp(a) and yet it need to be regarded as a scientific progress in understanding human biology and cardiovascular risk factors.
Lp(a) remains a well-established, inherited cardiovascular risk factor.
For patients, the message is clear: cardiovascular risk remains multifactorial, and optimizing LDL‑C and comorbidities is more important than ever.
- Lp(a) lowering alone may not be enough — residual risk from LDL‑C, inflammation, diabetes, hypertension, and obesity still drives events.
- LDL‑C long term management and optimization remains the strongest proven lever for reducing ASCVD risk.
- Comorbidity control (diabetes, blood pressure, weight, kidney disease, smoking) is decisive for long‑term outcomes.
The Opportunity Ahead:
Pelacarsen’s results don’t close the door on Lp(a) therapies — they sharpen our focus.
Patients benefit most when LDL‑C is aggressively lowered, risk factors are controlled, and new therapies are integrated thoughtfully as evidence evolves.
This post reflects my personal views and interpretation of recent scientific data. It is not an official Novartis communication and does not represent the position, strategy, or endorsement of my employer.”
Stay updated with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience